PMV Pharmaceuticals (PMVP) AI Stock Analysis

• Market Cap: $77.90M
• Dividend Yield: N/A
• Average Volume (3M): 2.02M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.49
• Revenue Growth: N/A
• EPS Growth: -61.41%
• Country: US
• Employees: 47
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.41
• Shares Outstanding: 52,990,864
• 10 Day Avg. Volume: 703,051
• 30 Day Avg. Volume: 2,020,557
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -1.11
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 2.69K
• Enterprise Value/Ebitda: 0.96
• 1Y Price Target: $5.00
• Price Target Upside: 216.46% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 40 Underperform
• Price Target: ―

PMV Pharmaceuticals faces significant challenges typical of a biotech firm in the pre-commercialization phase, with no revenue and high R&D costs leading to negative financials. The strong cash position offers some financial flexibility, but the lack of revenue and ongoing losses are significant concerns. Technical indicators suggest a bearish trend, and valuation metrics reflect the company's developmental stage. A path to commercialization is essential for improving financial health and investor confidence.

Positive Factors

Strong Cash Position

A strong cash position provides financial flexibility, allowing PMV Pharmaceuticals to continue funding R&D efforts and withstand operational losses until commercialization milestones are achieved.

Low Debt Levels

Low debt levels reduce financial risk and interest burden, enabling the company to focus resources on advancing its drug pipeline without the pressure of significant debt repayments.

Focus on p53 Mutations

Targeting p53 mutations positions PMV Pharmaceuticals to address a significant unmet need in cancer treatment, potentially leading to breakthrough therapies and strong market demand upon successful development.

Negative Factors

Lack of Revenue

The absence of revenue generation highlights the company's reliance on external funding and the critical need to achieve commercialization to improve financial health and investor confidence.

Negative Cash Flows

Negative cash flows indicate high operational cash usage, necessitating reliance on external financing, which poses a risk if capital markets become less favorable, potentially impacting long-term sustainability.

Increasing Losses

Increasing losses reflect high operational costs without offsetting revenue, underscoring the urgency for PMV Pharmaceuticals to achieve successful drug commercialization to move towards profitability.

PMV Pharmaceuticals Business Overview & Revenue Model

Company Description

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.

How the Company Makes Money

PMV Pharmaceuticals generates revenue primarily through the development and commercialization of its proprietary drug candidates. The company focuses on advancing its pipeline of small-molecule therapies through clinical trials and aims to monetize these assets via out-licensing agreements, partnerships with larger pharmaceutical companies, or direct sales upon regulatory approval. Key revenue streams include milestone payments, royalties, and upfront fees from partnerships and collaborations, which are essential to funding ongoing research and development efforts. The company's financial success is closely tied to the successful advancement of its drug candidates through clinical trials and obtaining necessary regulatory approvals.

PMV Pharmaceuticals Financial Statement Overview

Summary

PMV Pharmaceuticals is typical of a biotech company in its pre-revenue phase, with significant R&D investments leading to high operational losses and negative cash flows. The strong cash position provides some financial flexibility, but the ongoing lack of revenue generation is a critical issue. The company needs to achieve milestones that could lead to commercialization to improve its financial health and investor confidence.

Income Statement

PMV Pharmaceuticals has consistently reported zero revenue over the years, highlighting the typical operational phase of a biotech firm focused on R&D before product commercialization. The net income is negative, with increasing losses, indicating high operational expenses relative to non-existent revenues. The absence of revenue growth and weak profit margins reflect challenges in moving towards profitability.

Balance Sheet

The company's balance sheet shows a strong equity position with significant cash reserves, providing a buffer against the continued losses. The debt-to-equity ratio is low due to minimal debt levels, which is a positive sign. However, the continuous decline in stockholders' equity and asset base over the years is a concern, indicating potential long-term sustainability issues if the trend continues without revenue generation.

Cash Flow

PMV Pharmaceuticals exhibits negative operating and free cash flows, consistent with its stage in the biotech lifecycle. While free cash flow has improved slightly, it remains negative, reflecting high operational cash usage. The lack of positive cash flow from operations indicates reliance on external financing to sustain operations, posing a risk if capital markets become less favorable.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-32.00K	0.00	-1.26M	-650.00K	-1.28M	-318.00K
EBITDA	-89.38M	-73.67M	-78.88M	-76.72M	-57.99M	-34.62M
Net Income	-80.87M	-58.71M	-68.96M	-73.32M	-57.85M	-34.44M
Balance Sheet
Total Assets	152.85M	191.29M	252.15M	270.31M	331.57M	365.53M
Cash, Cash Equivalents and Short-Term Investments	142.27M	169.45M	203.06M	241.05M	297.16M	361.42M
Total Debt	1.02M	1.19M	13.29M	13.98M	11.19M	0.00
Total Liabilities	12.25M	15.21M	26.46M	24.28M	23.01M	6.41M
Stockholders Equity	140.60M	176.08M	225.69M	246.03M	308.56M	359.12M
Cash Flow
Free Cash Flow	-70.14M	-51.94M	-56.62M	-71.74M	-47.92M	-32.89M
Operating Cash Flow	-70.07M	-51.28M	-55.66M	-63.76M	-46.57M	-32.74M
Investing Cash Flow	64.56M	53.35M	-50.55M	-1.37M	-143.58M	27.91M
Financing Cash Flow	285.00K	313.00K	35.58M	958.00K	2.02M	292.97M

PMV Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.58
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PMVP, the sentiment is Positive. The current price of 1.58 is above the 20-day moving average (MA) of 1.43, above the 50-day MA of 1.42, and above the 200-day MA of 1.25, indicating a bullish trend. The MACD of 0.04 indicates Negative momentum. The RSI at 62.12 is Neutral, neither overbought nor oversold. The STOCH value of 93.11 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PMVP.

PMV Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GANX	46 Neutral	$67.22M	―	-240.21%	―	―	49.82%
XFOR	44 Neutral	$69.59M	―	-207.22%	―	5721.31%	-671.01%
ABVC	43 Neutral	$70.63M	―	-39.93%	―	186.84%	89.16%
PMVP	40 Underperform	$77.90M	―	-45.57%	―	―	-61.41%
PRLD	35 Underperform	$67.35M	―	-96.33%	―	―	7.72%